{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-007369","form_type":"8-K","ticker":"BTCY","cik":"0001630113","company_name":"BIOTRICITY INC.","filed_at":"2026-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.685001+00:00","generated_at":"2026-05-16T02:05:11.288969+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biotricity Q3 FY26 revenue up 10% to $4M; net loss narrows 13% to $1.1M","bullets":["Revenue $4M (+10.2% YoY); gross margin expanded to 81.5% from 76.4%.","Net loss $1.1M ($0.042 per share) vs $1.3M ($0.054 per share) prior year.","Third consecutive quarter of positive EBITDA and net operating income.","Recurring TaaS revenue $3.6M (91.2% of total); customer retention 90%+.","FDA clearance for AI clinical model expected in coming months."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-007369","json":"https://secwatch.observer/filing/0001493152-26-007369.json","markdown":"https://secwatch.observer/filing/0001493152-26-007369.md","text":"https://secwatch.observer/filing/0001493152-26-007369.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630113/000149315226007369/0001493152-26-007369-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630113/000149315226007369/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:05:11.288969+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}